Incorporating progesterone receptor expression into the PREDICT breast prognostic model.

Breast Neoplasms / pathology Female Humans Progesterone Prognosis Receptor, ErbB-2 / metabolism Receptors, Progesterone / metabolism
PREDICT Breast Progesterone receptor Prognosis breast cancer

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 24 11 2021
revised: 30 05 2022
accepted: 03 06 2022
pubmed: 8 8 2022
medline: 1 9 2022
entrez: 7 8 2022
Statut: ppublish

Résumé

Predict Breast (www.predict.nhs.uk) is an online prognostication and treatment benefit tool for early invasive breast cancer. The aim of this study was to incorporate the prognostic effect of progesterone receptor (PR) status into a new version of PREDICT and to compare its performance to the current version (2.2). The prognostic effect of PR status was based on the analysis of data from 45,088 European patients with breast cancer from 49 studies in the Breast Cancer Association Consortium. Cox proportional hazard models were used to estimate the hazard ratio for PR status. Data from a New Zealand study of 11,365 patients with early invasive breast cancer were used for external validation. Model calibration and discrimination were used to test the model performance. Having a PR-positive tumour was associated with a 23% and 28% lower risk of dying from breast cancer for women with oestrogen receptor (ER)-negative and ER-positive breast cancer, respectively. The area under the ROC curve increased with the addition of PR status from 0.807 to 0.809 for patients with ER-negative tumours (p = 0.023) and from 0.898 to 0.902 for patients with ER-positive tumours (p = 2.3 × 10 The inclusion of the prognostic effect of PR status to PREDICT Breast has led to an improvement of model performance and more accurate absolute treatment benefit predictions for individual patients. Further studies should determine whether the baseline hazard function requires recalibration.

Sections du résumé

BACKGROUND
Predict Breast (www.predict.nhs.uk) is an online prognostication and treatment benefit tool for early invasive breast cancer. The aim of this study was to incorporate the prognostic effect of progesterone receptor (PR) status into a new version of PREDICT and to compare its performance to the current version (2.2).
METHOD
The prognostic effect of PR status was based on the analysis of data from 45,088 European patients with breast cancer from 49 studies in the Breast Cancer Association Consortium. Cox proportional hazard models were used to estimate the hazard ratio for PR status. Data from a New Zealand study of 11,365 patients with early invasive breast cancer were used for external validation. Model calibration and discrimination were used to test the model performance.
RESULTS
Having a PR-positive tumour was associated with a 23% and 28% lower risk of dying from breast cancer for women with oestrogen receptor (ER)-negative and ER-positive breast cancer, respectively. The area under the ROC curve increased with the addition of PR status from 0.807 to 0.809 for patients with ER-negative tumours (p = 0.023) and from 0.898 to 0.902 for patients with ER-positive tumours (p = 2.3 × 10
CONCLUSION
The inclusion of the prognostic effect of PR status to PREDICT Breast has led to an improvement of model performance and more accurate absolute treatment benefit predictions for individual patients. Further studies should determine whether the baseline hazard function requires recalibration.

Identifiants

DOI: 10.1016/j.ejca.2022.06.011 PMID: 35933885 PMC: PMC10412460
pubmed: 35933885
pii: S0959-8049(22)00362-8
doi: 10.1016/j.ejca.2022.06.011
pmc: PMC10412460
pii:
doi:

Substances chimiques

Receptors, Progesterone 0
Progesterone 4G7DS2Q64Y
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-193

Subventions

Organisme : Wellcome Trust
ID : 203477/Z/16/Z
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Clin Cancer Res. 2006 Aug 1;12(15):4614-8
pubmed: 16899609
J Cancer. 2016 Jun 23;7(10):1281-94
pubmed: 27390604
Breast Cancer Res Treat. 2014 Nov;148(1):143-51
pubmed: 25253172
PLoS Med. 2010 May 25;7(5):e1000279
pubmed: 20520800
Mod Pathol. 2019 Sep;32(9):1244-1256
pubmed: 30976105
J Clin Oncol. 2005 Oct 20;23(30):7721-35
pubmed: 16234531
Br J Cancer. 2014 Feb 4;110(3):565-72
pubmed: 24300977
Breast Cancer Res. 2010;12(1):R1
pubmed: 20053270
Br J Cancer. 2012 Aug 21;107(5):800-7
pubmed: 22850554
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
BMC Cancer. 2018 Sep 17;18(1):897
pubmed: 30223800
Br J Cancer. 2009 Jun 2;100(11):1806-11
pubmed: 19401693
BMC Cancer. 2014 Dec 03;14:908
pubmed: 25472026
J Clin Oncol. 2003 May 15;21(10):1973-9
pubmed: 12743151
Breast Cancer Res. 2017 May 22;19(1):58
pubmed: 28532503
J Zhejiang Univ Sci B. 2010 Jan;11(1):1-9
pubmed: 20043345
J Clin Pathol. 1996 Nov;49(11):920-5
pubmed: 8944613
Ann Oncol. 2006 May;17(5):818-26
pubmed: 16497822

Auteurs

Isabelle Grootes (I)

University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK. Electronic address: ig345@medschl.cam.ac.uk.

Renske Keeman (R)

The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, 1066 CX, the Netherlands.

Fiona M Blows (FM)

University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK.

Roger L Milne (RL)

Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, 3004, Australia; The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, Victoria, 3010, Australia; Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Victoria, 3168, Australia.

Graham G Giles (GG)

Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, 3004, Australia; The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, Victoria, 3010, Australia; Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Victoria, 3168, Australia.

Anthony J Swerdlow (AJ)

The Institute of Cancer Research, Division of Genetics and Epidemiology, London, SM2 5NG, UK; The Institute of Cancer Research, Division of Breast Cancer Research, London, SW7 3RP, UK.

Peter A Fasching (PA)

University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, 90095, USA; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.

Mustapha Abubakar (M)

National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 20850, USA.

Irene L Andrulis (IL)

Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, M5G 1X5, Canada; University of Toronto, Department of Molecular Genetics, Toronto, ON, M5S 1A8, Canada.

Hoda Anton-Culver (H)

University of California Irvine, Department of Medicine, Genetic Epidemiology Research Institute, Irvine, CA, 92617, USA.

Matthias W Beckmann (MW)

Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.

Carl Blomqvist (C)

University of Helsinki, Department of Oncology, Helsinki University Hospital, Helsinki, 00290, Finland; Örebro University Hospital, Department of Oncology, Örebro, 70185, Sweden.

Stig E Bojesen (SE)

Copenhagen University Hospital, Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, 2730, Denmark; Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, 2730, Denmark; University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, 2200, Denmark.

Manjeet K Bolla (MK)

University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, CB1 8RN, UK.

Bernardo Bonanni (B)

IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, 20141, Italy.

Ignacio Briceno (I)

Universidad de La Sabana, Medical Faculty, Bogota, 140013, Colombia.

Barbara Burwinkel (B)

German Cancer Research Center (DKFZ), Molecular Epidemiology Group, C080, Heidelberg, 69120, Germany; University of Heidelberg, Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, Heidelberg, 69120, Germany.

Nicola J Camp (NJ)

University of Utah, Department of Internal Medicine and Huntsman Cancer Institute, Salt Lake City, UT, 84112, USA.

Jose E Castelao (JE)

Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Oncology and Genetics Unit, Vigo, 36312, Spain.

Ji-Yeob Choi (JY)

Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, 03080, South Korea; Seoul National University, Cancer Research Institute, Seoul, 03080, South Korea; Seoul National University Medical Research Center, Institute of Health Policy and Management, Seoul, 03080, South Korea.

Christine L Clarke (CL)

University of Sydney, Westmead Institute for Medical Research, Sydney, New South Wales, 2145, Australia.

Fergus J Couch (FJ)

Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, 55905, USA.

Angela Cox (A)

University of Sheffield, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Sheffield, S10 2TN, UK.

Simon S Cross (SS)

University of Sheffield, Academic Unit of Pathology, Department of Neuroscience, Sheffield, S10 2TN, UK.

Kamila Czene (K)

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden.

Peter Devilee (P)

Leiden University Medical Center, Department of Pathology, Leiden, 2333 ZA, the Netherlands; Leiden University Medical Center, Department of Human Genetics, Leiden, 2333 ZA, the Netherlands.

Thilo Dörk (T)

Hannover Medical School, Gynaecology Research Unit, Hannover, 30625, Germany.

Alison M Dunning (AM)

University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK.

Miriam Dwek (M)

University of Westminster, School of Life Sciences, London, W1B 2HW, UK.

Douglas F Easton (DF)

University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, CB1 8RN, UK.

Diana M Eccles (DM)

University of Southampton, Faculty of Medicine, Southampton, SO17 1BJ, UK.

Mikael Eriksson (M)

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden.

Kristina Ernst (K)

University Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.

D Gareth Evans (DG)

University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, M13 9WL, UK; St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, M13 9WL, UK.

Jonine D Figueroa (JD)

National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 20850, USA; The University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, EH16 4UX, UK; The University of Edinburgh, Cancer Research UK Edinburgh Centre, Edinburgh, EH4 2XR, UK.

Visnja Fink (V)

University Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.

Giuseppe Floris (G)

Leuven Cancer Institute, University Hospitals Leuven, Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven, 3000, Belgium.

Stephen Fox (S)

Peter MacCallum Cancer Center, Melbourne, Victoria, Australia, 3000.

Marike Gabrielson (M)

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden.

Manuela Gago-Dominguez (M)

Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, 15706, Spain; University of California San Diego, Moores Cancer Center, La Jolla, CA, 92037, USA.

José A García-Sáenz (JA)

Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Medical Oncology Department, Hospital Clínico San Carlos, Madrid, 28040, Spain.

Anna González-Neira (A)

Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, 28029, Spain.

Lothar Haeberle (L)

Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.

Christopher A Haiman (CA)

University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, 90033, USA.

Per Hall (P)

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden; Södersjukhuset, Department of Oncology, Stockholm, 118 83, Sweden.

Ute Hamann (U)

German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 69120, Germany.

Elaine F Harkness (EF)

University of Manchester, Manchester Academic Health Science Centre, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester, M13 9PT, UK; Wythenshawe Hospital, Manchester University NHS Foundation Trust, Nightingale & Genesis Prevention Centre, Manchester, M23 9LT, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Unit, Manchester, M13 9WL, UK.

Mikael Hartman (M)

National University of Singapore and National University Health System, Saw Swee Hock School of Public Health, Singapore, 119077, Singapore; National University Health System, Department of Surgery, Singapore, 119228, Singapore.

Alexander Hein (A)

Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.

Maartje J Hooning (MJ)

Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, 3015 GD, the Netherlands.

Ming-Feng Hou (MF)

Kaohsiung Municipal Hsiao-Kang Hospital, Department of Surgery, Kaohsiung, 812, Taiwan.

Sacha J Howell (SJ)

University of Manchester, Division of Cancer Sciences, Manchester, M13 9PL, UK.
University of Sydney, Australian Breast Cancer Tissue Bank, Westmead Institute for Medical Research, Sydney, New South Wales, 2145, Australia.
Peter MacCallum Cancer Center, Research Department, Melbourne, Victoria, Australia, 3000; The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Victoria, 3000, Australia.

Hidemi Ito (H)

Aichi Cancer Center Research Institute, Division of Cancer Information and Control, Nagoya, 464-8681, Japan; Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, 466-8550, Japan.

Anna Jakubowska (A)

Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, 71-252, Poland; Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic Diagnostics, Szczecin, 71-252, Poland.

Wolfgang Janni (W)

University Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.

Esther M John (EM)

Stanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, 94304, USA.

Audrey Jung (A)

German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, 69120, Germany.

Daehee Kang (D)

Seoul National University, Cancer Research Institute, Seoul, 03080, South Korea; Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, 03080, South Korea.

Vessela N Kristensen (VN)

Oslo University Hospital and University of Oslo, Department of Medical Genetics, Oslo, 0379, Norway; University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, 0450, Norway.

Ava Kwong (A)

Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong; The University of Hong Kong, Department of Surgery, Hong Kong; Hong Kong Sanatorium and Hospital, Department of Surgery and Cancer Genetics Center, Hong Kong.

Diether Lambrechts (D)

VIB Center for Cancer Biology, VIB, Leuven, 3001, Belgium; University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, 3000, Belgium.

Jingmei Li (J)

Genome Institute of Singapore, Human Genetics Division, Singapore, 138672, Singapore.

Jan Lubiński (J)

Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, 71-252, Poland.

Mehdi Manoochehri (M)

German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 69120, Germany.

Sara Margolin (S)

Södersjukhuset, Department of Oncology, Stockholm, 118 83, Sweden; Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, 118 83, Sweden.

Keitaro Matsuo (K)

Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, 466-8550, Japan; Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention, Nagoya, 464-8681, Japan.

Nur Aishah Mohd Taib (NAM)

University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, 50603, Malaysia.

Anna Marie Mulligan (AM)

University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, M5S 1A8, Canada; University Health Network, Laboratory Medicine Program, Toronto, ON, M5G 2C4, Canada.

Heli Nevanlinna (H)

University of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, 00290, Finland.

William G Newman (WG)

University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, M13 9WL, UK; St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, M13 9WL, UK.

Kenneth Offit (K)

Memorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, New York, NY, 10065, USA; Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of Medicine, New York, NY, 10065, USA.

Ana Osorio (A)

Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, 28029, Spain; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.

Sue K Park (SK)

Seoul National University, Cancer Research Institute, Seoul, 03080, South Korea; Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, 03080, South Korea; Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul, 03080, South Korea.

Tjoung-Won Park-Simon (TW)

Hannover Medical School, Gynaecology Research Unit, Hannover, 30625, Germany.

Alpa V Patel (AV)

American Cancer Society, Department of Population Science, Atlanta, GA, 30303, USA.

Nadege Presneau (N)

University of Westminster, School of Life Sciences, London, W1B 2HW, UK.

Katri Pylkäs (K)

University of Oulu, Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, Oulu, 90570, Finland; Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumor Biology, Oulu, 90570, Finland.

Brigitte Rack (B)

University Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.

Paolo Radice (P)

Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Milan, 20133, Italy.

Gad Rennert (G)

Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, 35254, Israel.

Atocha Romero (A)

Hospital Universitario Puerta de Hierro, Medical Oncology Department, Madrid, 28222, Spain.

Emmanouil Saloustros (E)

University Hospital of Larissa, Department of Oncology, Larissa, 411 10, Greece.

Elinor J Sawyer (EJ)

King's College London, School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy's Campus, London, UK.

Andreas Schneeweiss (A)

University of Heidelberg, Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, Heidelberg, 69120, Germany; University Hospital and German Cancer Research Center, National Center for Tumor Diseases, Heidelberg, 69120, Germany.

Fabienne Schochter (F)

University Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.

Minouk J Schoemaker (MJ)

The Institute of Cancer Research, Division of Genetics and Epidemiology, London, SM2 5NG, UK.

Chen-Yang Shen (CY)

Academia Sinica, Institute of Biomedical Sciences, Taipei, 115, Taiwan; China Medical University, School of Public Health, Taichung, Taiwan.

Rana Shibli (R)

Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, 35254, Israel.

Peter Sinn (P)

University Hospital Heidelberg, Department of Pathology, Institute of Pathology, Heidelberg, 69120, Germany.

William J Tapper (WJ)

University of Southampton, Faculty of Medicine, Southampton, SO17 1BJ, UK.

Essa Tawfiq (E)

University of Auckland, Auckland, New Zealand.

Soo Hwang Teo (SH)

University of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, 50603, Malaysia; Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor, 47500, Malaysia.

Lauren R Teras (LR)

American Cancer Society, Department of Population Science, Atlanta, GA, 30303, USA.

Diana Torres (D)

German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 69120, Germany; Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, 110231, Colombia.

Celine M Vachon (CM)

Mayo Clinic, Department of Quantitative Health Sciences, Division of Epidemiology, Rochester, MN, 55905, USA.

Carolien H M van Deurzen (CHM)

Erasmus University Medical Center, Department of Pathology, Rotterdam, 3015 CN, the Netherlands.

Camilla Wendt (C)

Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, 118 83, Sweden.

Justin A Williams (JA)

University of Utah, Department of Internal Medicine and Huntsman Cancer Institute, Salt Lake City, UT, 84112, USA.

Robert Winqvist (R)

University of Oulu, Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, Oulu, 90570, Finland; Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumor Biology, Oulu, 90570, Finland.

Mark Elwood (M)

University of Auckland, Auckland, New Zealand.

Marjanka K Schmidt (MK)

The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, 1066 CX, the Netherlands; The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Psychosocial Research and Epidemiology, Amsterdam, 1066 CX, the Netherlands.

Montserrat García-Closas (M)

National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 20850, USA.

Paul D P Pharoah (PDP)

University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, CB1 8RN, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Incorporating progesterone receptor expression...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Incorporating progesterone receptor expression...
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de la progestérone › Progestérone › Incorporating progesterone receptor expression...
questionsmedicales.fr › Diagnostic › Pronostic › Incorporating progesterone receptor expression...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Incorporating progesterone receptor expression...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs à la progestérone › Incorporating progesterone receptor expression...